Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:84-90

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romppanen, H.
Right arrow Articles by Ruskoaho, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romppanen, H.
Right arrow Articles by Ruskoaho, H.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Other myocardial biology
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Hypertrophy
Right arrow Physiological and pathological control of gene expression

(Hypertension. 2001;37:84.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Endothelin-1–Independent and Angiotensin II–Independent Induction of Adrenomedullin Gene Expression

Hannu Romppanen; Jutta Puhakka; Gábor Földes; István Szokodi; Olli Vuolteenaho; Heikki Tokola; Miklós Tóth; Heikki Ruskoaho

From the Departments of Pharmacology and Toxicology (H.R., J.P., I.S., H.T., H.R.) and Physiology (O.V.), Biocenter Oulu, University of Oulu (Finland); and the First Department of Medicine (G.F., M.T.), Semmelweis University, Budapest, Hungary.

Correspondence to Heikki Ruskoaho, MD, PhD, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Oulu, PO Box 5000, 90014 University of Oulu, Finland. E-mail heikki.ruskoaho{at}oulu.fi

Abstract—Adrenomedullin (AM) may function as an autocrine and/or paracrine factor in the heart, but the exact mechanisms regulating cardiac AM gene expression are unknown. The aim of the present study was to characterize the precise time course of induction of atrial and ventricular AM gene expression during pressure overload and to study whether endothelin-1 or angiotensin II plays a causal role in the activation of cardiac AM gene expression. The pressure overload was produced by arginine-vasopressin (AVP, 0.05 µg/kg per minute IV) infusion for 15 minutes, 30 minutes, 1 hour, 2 hours, or 4 hours in conscious rats. A significant increase in left ventricular AM mRNA levels was seen after 2 hours of pressure overload in the left ventricle and after 30 minutes in the left atrium. The left atrial immunoreactive AM (ir-AM) levels decreased significantly after 2 hours of pressure overload. Plasma ir-AM levels increased slightly in response to 4 hours of AVP infusion. Bolus injections of bosentan (mixed ETA/ETB receptor antagonist, 10 mg/kg IV), losartan (AT1 receptor antagonist, 10 mg/kg IV), and their combination had no effect on the increase of cardiac AM mRNA and ir-AM levels produced by 2 hours of pressure overload. In addition, losartan, bosentan, and their combination did not affect plasma ir-AM levels in the vehicle-infused and AVP-infused animals. The present study indicates that cardiac AM gene expression is rapidly upregulated in response to pressure. The induction of ventricular and atrial AM gene expression by pressure overload is angiotensin II–independent and endothelin-1–independent.


Key Words: adrenomedullin • gene expression • angiotensin II • endothelin